oncotherapysolutions.com
Home PageHome Page
http://www.oncotherapysolutions.com/
Home Page
http://www.oncotherapysolutions.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
0.1 seconds
16x16
32x32
64x64
128x128
160x160
192x192
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
United States
View this contact
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
United States
View this contact
Domains By Proxy, LLC
Registration Private
Domain●●●●●●xy.com
14747 N Norths●●●●●●●●●●●●●●e 111, PMB 309
Sco●●●ale , Arizona, 85260
United States
View this contact
BUY YOUR DOMAIN
12
YEARS
11
MONTHS
24
DAYS
GODADDY.COM, LLC
WHOIS : whois.godaddy.com
REFERRED : http://registrar.godaddy.com
PAGES IN
THIS WEBSITE
5
SSL
EXTERNAL LINKS
0
SITE IP
184.168.192.95
LOAD TIME
0.063 sec
SCORE
6.2
Home Page | oncotherapysolutions.com Reviews
https://oncotherapysolutions.com
Home Page
oncotherapysolutions.com
News
http://www.oncotherapysolutions.com/News.html
Cutting edge technologies and innovative oncology drugs. IND-enabling studies on triple-negative breast cancers with the goal to move. To clinical trials and seek Fast-Track FDA approval to help patients with triple-negative breast cancers. Our drug conjugate is also expected to be highly potent against other solid tumors including prostate, ovarian, pancreatic, colon, lung and brain cancers. 6/26/2014: Oncotherapy Solutions is pleased to announce that it was able with its partners to successfully manufa...
Career
http://www.oncotherapysolutions.com/Career.html
We are interested in highly motivated, goal-oriented and established scientists with expertise in drug design, drug development, PK/PD, metabolism and toxicology. Studies for small molecule and nanoparticle anti-cancer therapeutics. Additional knowledge and expertise in FDA. Are most welcome. We thrive to be a standalone biotech company providing highly effective, safer and affordable cancer drugs to benefit cancer patients. Description of future open positions will be announced shortly.
Home Page
http://www.oncotherapysolutions.com/Home_Page.html
Focusing on scientific discovery and innovation to save human lives. Cancer is the second most common cause of death in the US, exceeded only by heart disease. One of every four deaths in the United States is due to cancer. The American Cancer Society estimates that in 2014, about 1,665,540 Americans were diagnosed with invasive cancer, and 585,720 Americans died of this disease. The company currently has three preclinical programs:. The first program is focused on the development of novel, potent and sa...
Licensing & Partnerships
http://www.oncotherapysolutions.com/Licensing___Partnerships.html
We value the contribution of our current and future strategic partners and collaborators. The company is seeking pharmaceutical and biotechnology partners to work with to advance its preclinical programs and get top drug candidates/delivery systems ready for clinical trials. Our delivery systems and drug candidates have the potential to be targeted to cancer cells, to be potent, stable and safer than pre-existing therapies . Oncotherapy Solutions, LLC. Management has strong background in biotech project ...
Management
http://www.oncotherapysolutions.com/Management.html
Najib Lamharzi, PhD. Leadership, expertise and dedication to scientific excellence. Is currently President/CEO and founder of Oncotherapy Solutions, LLC. While at Nastech, he worked in collaborative projects with Merck, Procter and Gamble and Par Pharmaceuticals. Dr. Lamharzi also trained PhD scientists and. In cell biology, molecular biology, drug formulation and delivery. Dr. Lamharzi gained further expertise in drug delivery, development of. From 1999-2004, Dr. Lamharzi worked at the Fred Hutchins...
TOTAL PAGES IN THIS WEBSITE
5
OncoTherapy Science, Inc.
がん特異的ペプチドワクチン S-588410 第 相臨床試験進捗 最終患者登録 に関するお知らせ. 当社連結子会社と Thermo Fisher Scientific との新規リキッドバイオプシープラットフォーム評価のための提携についてのお知らせ. オンコセラピー サイエンス OTS では、がん分子標的治療薬の開発に適した標的遺伝子を多数同定しています。 血液 組織などの検体中に存在しているT細胞のTCR遺伝子配列情報を、次世代シーケンサーを用いて網羅的に取得し詳細に解析する T細胞受容体 TCR 解析サービス。 私たちは、 より治療効果が高く、より副作用の少ないがん治療薬 治療法を、一日も早くがんに苦しむ患者さんに届けること、がんとの闘いに勝つこと を目指し、ジェノミックスを医療分野に先駆者としてもたらした中村祐輔教授とともに、研究 開発に取り組んでいます。
US OncoTherapy systems BioMedicine Group
Oncotherapy Network
We've noticed that you're using an ad blocker. Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker. How do I disable my ad blocker? How to disable your ad blocker for our site:. Adblock / Adblock Plus. Click on the AdBlock / AdBlock Plus icon on the top right of your browser. Click Don’t run on pages on this domain. OR Enabled on this site. Close this help box and click "It's off now". Dec 21, 2017.
SD-IORT > Home
How to book SD-IORT. Information for existing users. Early stage breast cancer. Am I suitable for SD-IORT? How does SD-IORT work? Where is SD-IORT available? For the Healthcare Professional. Information on the system. Where is SD-IORT available? How to book SD-IORT. Information for existing users. Early stage breast cancer. Am I suitable for SD-IORT? How does SD-IORT work? Where is SD-IORT available? For the Healthcare Professional. Information on the system. Where is SD-IORT available? You are here: Home.
Home Page
Focusing on scientific discovery and innovation in targeted therapy and immuno-oncology to save human lives:. Cancer is the second most common cause of death in the US, exceeded only by heart disease. One of every four deaths in the United States is due to cancer. The American Cancer Society estimates that in 2014, about 1,665,540 Americans were diagnosed with invasive cancer, and 585,720 Americans died of this disease. The company currently has three preclinical programs:. Preclinical studies of these d...
Oncotherex | Cancers du sein et de l'ovaire
Cancers du sein et de l'ovaire. Cancers du sein et de l'ovaire. Oncotherex est spécialisée dans la mise en culture de tumeurs du sein et de l'ovaire permettant de tester l'efficacité thérapeutique de molécules innovantes. En savoir plus sur Oncotherex. Vous êtes une start-up, un laboratoire académique ou une entreprise pharmaceutique et vous souhaitez tester des molécules innovantes, venez vite découvrir nos offres. Oncotherex propose de nombreux tests sur ses tumeurs du sein et de l'ovaire. Bienvenue su...
OncoTherics News
Latest news and events from Oncotherics. Wednesday, 17 December 2014. OncoTherics signs collaboration agreement with University of Cambridge. OncoTherics has signed a collaboration agreement with the University of Cambridge to progress a series of novel preclinical investigations using OCT1002 in Pancreatic Tumour models. The investigations will augment OncoTherics formal preclinical studies, providing useful additional information about OCT1002 in Pancreatic Cancer. Wednesday, 16 July 2014. Weiss Medall...
Oncotherix / InCell-RT™
Oncotherix™ is a clinical stage oncology company developing InCell-RT™. Herapy) for the treatment of locally-advanced cancers. InCell-RT is DNA-ligated nanometer-scale intracellular radiotherapy locally administered via catheter-based infusion systems. Oncotherix is developing InCell-RT as a safer and more effective treatment for numerous locally-advanced cancers, starting with recurrent ovarian cancer and high grade glioma brain cancer. Therapeutic Advantages of InCell-RT. 12635 E. Montview Blvd.
Oncotherm
